MicroPort

Rice Biotech Launch Pad adds William McKeon to external advisory board

Retrieved on: 
Thursday, March 14, 2024
Harris Health System, Research, Launch pad, Growth, Bill, Goldman Sachs, Rice University, Trustee, Integration, Patient, Stanford University Medical Center, Neuroscience, University, Faculty, Medtronic, MicroPort, CTMC, Roger Williams University, Texas Medical Center, Argonne National Laboratory, Rice, Jefferies, Greater Houston Partnership, College of Engineering (KNUST), MD Anderson Cancer Center, McKeon, Pharmaceutical industry

HOUSTON, March 14, 2024 /PRNewswire/ -- Rice University today announced the addition of William McKeon to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.

Key Points: 
  • HOUSTON, March 14, 2024 /PRNewswire/ -- Rice University today announced the addition of William McKeon to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • "The appointment of a figure like Bill McKeon, who heads the largest medical city in the world at TMC, to the Launch Pad's external advisory board marks another highpoint of our commitment to the city of Houston," said Paul Wotton , executive director and chairman of the Rice Biotech Launch Pad.
  • "We are delighted to welcome Bill McKeon to the Launch Pad's remarkable external advisory board as he is a truly skilled leader whose local influence and strategic guidance will help elevate the Rice Biotech Launch Pad as a source for clinical advancements," said Omid Veiseh , associate professor of bioengineering at Rice and faculty director of the accelerator.
  • "I am honored to join the exceptional advisory board of the Rice Biotech Launch Pad," said McKeon.

Acarix appoints Aamir Mahmood as new CEO

Retrieved on: 
Thursday, February 1, 2024
Multimedia, Growth, Lead, American College, Food, Veterans' affairs, Patient, YPO, FDA, Boston Scientific, Marketing, MBA, Cardiology, LivaNova, CRM, AGM, MicroPort, ACC, Organization, Management

STOCKHOLM, Feb. 1, 2024 /PRNewswire/ -- The Board of Acarix AB (publ) announces the immediate appointment of Aamir Mahmood as its new CEO, effective February 1.

Key Points: 
  • STOCKHOLM, Feb. 1, 2024 /PRNewswire/ -- The Board of Acarix AB (publ) announces the immediate appointment of Aamir Mahmood as its new CEO, effective February 1.
  • Mr. Mahmood succeeds Acting CEO Fred Colen and previous CEO Helen Ljungdahl Round.
  • "It is with great pleasure that the Board of Acarix announces the appointment of Aamir Mahmood as the new CEO to lead this exciting phase of rapid growth, especially in the US.
  • Aamir succeeds Helen Ljungdahl Round who was appointed CEO of Acarix in January of 2022.

Stereotaxis Reports 2023 Third Quarter Financial Results

Retrieved on: 
Thursday, November 9, 2023
Average cost, Abbott, Operating cost, NYSE, International, Genesis, Physician, MicroPort, Growth, Ecosystem, Magic, Patient, Robotics, Pharmaceutical industry, Video game, Stereotaxis

ST. LOUIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • ST. LOUIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2023.
  • “Stereotaxis continues to deliver commercial results and advance a robust innovation strategy, while maintaining financial discipline,” said David Fischel, Chairman and CEO.
  • At September 30, 2023, Stereotaxis had cash and cash equivalents, including restricted cash, of $23.0 million and no debt.
  • Stereotaxis will host a conference call and webcast today, November 9, 2023, at 10:00 a.m. Eastern Time.

Rapid Medical™ Gains Approval in China for the World’s Only Adjustable Thrombectomy Device

Retrieved on: 
Thursday, August 31, 2023
Research, Surgery, Medical Devices, Neurology, Biotechnology, Health, General Health, Other Science, Science, TIGER, Comparable, Stroke, Brain, Grand Rapids Medical Mile, MicroPort, Patient, Physician, Risk, National Medical Products Administration, Embolism, NMPA, Medical imaging

Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device.

Key Points: 
  • Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device.
  • With this milestone of National Medical Product Administration (NMPA) approval, TIGERTRIEVER becomes the first device to offer patient-specific solutions for removing blood clots from the brain to advance the treatment of ischemic stroke.
  • “This new approval for TIGERTRIEVER propels treatment for ischemic stroke patients in China,” says Ronen Eckhouse , co-founder and CEO at Rapid Medical.
  • Comparable, leading stent retrievers are self-expanding and static, which can lead to suboptimal clot removal and minimal vessel protection.

Live Long-Distance TeleRobotic Procedures to Highlight Stereotaxis Technology at Asia Pacific Heart Rhythm Symposium

Retrieved on: 
Wednesday, August 16, 2023
Cardiac cycle, Society, Atrial fibrillation, Hospital, MicroPort, Patient, Physician, Electrophysiology, Diagnosis, Cardiology, Congress, Robotics, NYSE, Medical device, Stereotaxis, EP

ST. LOUIS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions.

Key Points: 
  • ST. LOUIS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be the focus of multiple live long-distance telerobotic procedures at the upcoming Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions.
  • APHRS and the Society for Cardiac Robotic Navigation will host a joint session on September 2, 2023, during the APHRS annual congress.
  • APHRS is the first society organized in the Asia Pacific region to promote excellence and advancement in the diagnosis and treatment of patients with heart rhythm disease.
  • They provide a platform for professional education, sharing of cutting-edge science, demonstration of advanced and novel techniques, and interaction among international experts in the field of heart rhythm management.

China TAVR & TMV Market Report 2023: Growing Prevalence of Aortic Stents and Rising Approval of New TAVR Products - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 27, 2023
Medical Devices, Health, Venus, Urbanization, TMVR, Prevalence, Policy, TMV, Aortic stenosis, US, Medtronic, MicroPort, Patient, TAVR, Growth, R, Medical device

China's TAVR market is expected to reach US$2.60 billion in 2027, growing at a CAGR of 55.91%, for the duration spanning 2023-2027.

Key Points: 
  • China's TAVR market is expected to reach US$2.60 billion in 2027, growing at a CAGR of 55.91%, for the duration spanning 2023-2027.
  • While, the TMV market in China is forecasted to reach US$1832.05 million in 2027, rising at a CAGR of 146.50%, for the time period of 2023-2027.
  • Factors such as growing prevalence of aortic stenosis, rise in approval of new TAVR products, rise in geriatric population and rapid urbanization would drive the growth of the market.
  • The report provides a comprehensive analysis of the China TAVR and TMV Market.

China TAVR & TMV Market Report 2023: Decline in Prices of Transcatheter Mitral Valve Procedures Presents Opportunities

Retrieved on: 
Tuesday, May 30, 2023
Venus, Urbanization, Prevalence, Policy, COVID-19, TMV, Aortic stenosis, US, Medtronic, MicroPort, Patient, TAVR, Growth, R, Semiconductor, Pharmaceutical industry, Medical imaging

China TAVR market is expected to reach US$2.60 billion in 2027, growing at a CAGR of 55.91%, for the duration spanning 2023-2027.

Key Points: 
  • China TAVR market is expected to reach US$2.60 billion in 2027, growing at a CAGR of 55.91%, for the duration spanning 2023-2027.
  • The TMV market in China is forecasted to reach US$1832.05 million in 2027, rising at a CAGR of 146.50%, for the time period of 2023-2027.
  • A few notable trends may include rising penetration of TAVR and TMV procedures, decline in prices of transcatheter mitral valve procedures, upcoming major TMVI products and rise in complications in open-heart surgery.
  • The report provides a comprehensive analysis of the China TAVR and TMV Market.

FDA Approves Next Generation MicroPort CRM AlizeaTM and CeleaTM Pacemaker Systems

Retrieved on: 
Thursday, May 18, 2023
Seniors, Nanotechnology, Other Science, Pharmaceutical, Research, Software, Medical Devices, Hardware, Consumer, Data Management, Science, Technology, Clinical Trials, Cardiology, General Health, FDA, Biotechnology, Health, Infection, Cardiac electrophysiology, Workflow, Vega, Atrial fibrillation, Quality of life, National Association Medical Staff Services, MRI, MicroPort, Patient, Standard of care, Physician, Risk, Tesla, Longevity, Arrhythmia, Medical device, CRM

AlizeaTM and CeleaTM feature the AutoMRI mode, a groundbreaking algorithm invented by MicroPort CRM, that increases patients’ safety and quality of life when undergoing an MRI examination.

Key Points: 
  • AlizeaTM and CeleaTM feature the AutoMRI mode, a groundbreaking algorithm invented by MicroPort CRM, that increases patients’ safety and quality of life when undergoing an MRI examination.
  • Patients only need to visit their cardiologist once within ten days before their MRI scan to activate the MRI mode.
  • Patients implanted with AlizeaTM or CeleaTM are provided with the SmartView ConnectTM home monitor, which is placed next to their bed.
  • The approval of AlizeaTM, CeleaTM, and associated products is the latest in a number of FDA approvals for MicroPort in the U.S. Last year, MicroPort’s EasyFinderTM cardiac electrophysiology diagnostic catheters and PathBuilderTM transseptal puncture products received FDA approvals and will be distributed by the MicroPort CRM organization.

$38.879 Billion Heart Failure Devices Markets - Global Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 20, 2023
Health, Medical Devices, Cardiology, Heart failure, Prevalence, Boston Scientific, Abbott Laboratories, ECMO, CAD, SHD, Incidence, Medtronic, Edwards Lifesciences, MicroPort, Investment, Developed country, Medical tourism, Geography, Medical device, Pharmaceutical industry

The "Heart Failure Devices Global Market - Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Heart Failure Devices Global Market - Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.
  • The heart failure devices global market expected to grow at high single-digit CAGR from 2022 to 2029 to reach $38,879.9 million by 2029.
  • Factors such as increasing incidence of heart failure diseases, technological advancement in heart failure devices, rising geriatric population, and favorable reimbursement are the drivers, vast pipeline products, increase in funding and approvals are the opportunities.
  • The heart failure devices market based on products is segmented as cardiac rhythm products, cardiac assist devices (CAD), structural heart devices (SHD), ECMO and others (modulation devices).

Orthopedic Devices Market worth $48.1 billion | MarketsandMarkets

Retrieved on: 
Thursday, March 16, 2023
Stryker Corporation, Research, ITS, MicroPort, Quality of life, Johnson & Johnson, Posture, Roe, Accident, Smith & Nephew, DeRoyal, Hospital, NuVasive, Risk, Bleeding, Tetraplegia, Bone, Patient, Government, Ageing, Pain, Medtronic, Growth, Incidence, Sport, Safety, Toys "R" Us Canada, II, Pharmaceutical industry, Dentistry, Medical device, 3D printing, Nursing, Enovis

The Asia Pacific orthopedic devices market is projected to grow at the highest CAGR of 5.8% from 2022 to 2028.

Key Points: 
  • The Asia Pacific orthopedic devices market is projected to grow at the highest CAGR of 5.8% from 2022 to 2028.
  • In September 2022, Stryker Corporation introduced New Gamma4 Hip fracture nailing system to expand its orthopedic fixation devices product portfolio.
  • Orthopedic devices help to alleviate pain and improve the quality of life for patients suffering from various orthopedic conditions.
  • Orthopedic devices are minimally invasive, making them easy to use and less risky than traditional treatments.